Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan;84(2):244–252. doi: 10.1054/bjoc.2000.1590

The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas

S Maula 1, R L Huuhtanen 2, C P Blomqvist 3, T A Wiklund 2, P Laurila 4, R Ristamäki 5
PMCID: PMC2363706  PMID: 11161384

Abstract

In many malignant diseases the expression levels of CD44 and its splice variant v6 (CD44v6) have been associated with the prognosis. The purpose of this study was to investigate the clinical significance of CD44 in adult soft tissue sarcomas (STS). 133 STS patients with a limb or superficial trunk tumour treated at the Helsinki University Central Hospital in 1987–1993 with a median follow-up time of 68 months were included in this study. The expression of CD44 and CD44v6 was determined immunohistochemically on paraffin-embedded tumour samples. 95% of the tumours expressed CD44 and CD44v6 was detected in 57%. Strong CD44 expression was associated with low grade (P = 0.04) and small tumour size (P = 0.02). In diploid tumours the CD44 expression was correlated with low S-phase fraction (P = 0.001). High expression of both, CD44 in general as well as that of CD44v6, predicted a higher risk for local recurrence (CD44: P = 0.01 and CD44v6: P = 0.05). Low CD44v6 content of the primary tumour correlated with poor survival (P = 0.02). Determining the expression of CD44 or CD44v6 in a primary STS could be a valuable tool for selecting the group of patients who might benefit from intensified local tumour treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: soft-tissue sarcoma, CD44, CD44v6, prognosis, local recurrence

Full Text

The Full Text of this article is available as a PDF (394.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aho R., Kalimo H., Salmi M., Smith D., Jalkanen S. Binding of malignant lymphoid cells to the white matter of the human central nervous system: role of different CD44 isoforms, beta 1, beta 2 and beta 7 integrins, and L-selectin. J Neuropathol Exp Neurol. 1997 May;56(5):557–568. doi: 10.1097/00005072-199705000-00012. [DOI] [PubMed] [Google Scholar]
  2. Alvegård T. A., Berg N. O., Ranstam J., Rydholm A., Röser B. Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial. Acta Orthop Scand. 1989 Oct;60(5):517–521. doi: 10.3109/17453678909150114. [DOI] [PubMed] [Google Scholar]
  3. Belitsos P. C., Hildreth J. E., August J. T. Homotypic cell aggregation induced by anti-CD44(Pgp-1) monoclonal antibodies and related to CD44(Pgp-1) expression. J Immunol. 1990 Mar 1;144(5):1661–1670. [PubMed] [Google Scholar]
  4. Choong P. F., Akerman M., Willén H., Andersson C., Gustafson P., Alvegård T., Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS. 1995 Nov;103(11):797–805. doi: 10.1111/j.1699-0463.1995.tb01437.x. [DOI] [PubMed] [Google Scholar]
  5. Collin C., Godbold J., Hajdu S., Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol. 1987 Apr;5(4):601–612. doi: 10.1200/JCO.1987.5.4.601. [DOI] [PubMed] [Google Scholar]
  6. Collin F., Chassevent A., Bonichon F., Bertrand G., Terrier P., Coindra J. M. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. Cancer. 1997 Jun 15;79(12):2371–2379. doi: 10.1002/(sici)1097-0142(19970615)79:12<2371::aid-cncr11>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  7. Denning S. M., Le P. T., Singer K. H., Haynes B. F. Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol. 1990 Jan 1;144(1):7–15. [PubMed] [Google Scholar]
  8. Dirix L. Y., Van Oosterom A. T. Diagnosis and treatment of soft tissue sarcomas in adults. Curr Opin Oncol. 1995 Jul;7(4):340–348. doi: 10.1097/00001622-199507000-00009. [DOI] [PubMed] [Google Scholar]
  9. Günthert U., Hofmann M., Rudy W., Reber S., Zöller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991 Apr 5;65(1):13–24. doi: 10.1016/0092-8674(91)90403-l. [DOI] [PubMed] [Google Scholar]
  10. Herrlich P., Pals S., Ponta H. CD44 in colon cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1110–1112. doi: 10.1016/0959-8049(95)00252-e. [DOI] [PubMed] [Google Scholar]
  11. Hong R. L., Pu Y. S., Hsieh T. S., Chu J. S., Lee W. J. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol. 1995 Jun;153(6):2025–2028. [PubMed] [Google Scholar]
  12. Hudson D. L., Speight P. M., Watt F. M. Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them. Int J Cancer. 1996 May 16;66(4):457–463. doi: 10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  13. Huuhtanen R. L., Blomqvist C. P., Wiklund T. A., Böhling T. O., Virolainen M. J., Tukiainen E. J., Tribukait B., Andersson L. C. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer. 1999 Feb;79(5-6):945–951. doi: 10.1038/sj.bjc.6690151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huuhtanen R. L., Blomqvist C. P., Wiklund T. A., Virolainen M. J., Elomaa A. I., Pan Y., Tribukait B. S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome. Cancer. 1996 May 1;77(9):1815–1822. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1815::AID-CNCR9>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  15. Ishida T. Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. Surg Today. 2000;30(1):28–32. doi: 10.1007/PL00010042. [DOI] [PubMed] [Google Scholar]
  16. Jackson D. G., Bell J. I., Dickinson R., Timans J., Shields J., Whittle N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol. 1995 Feb;128(4):673–685. doi: 10.1083/jcb.128.4.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jacobson K., O'Dell D., Holifield B., Murphy T. L., August J. T. Redistribution of a major cell surface glycoprotein during cell movement. J Cell Biol. 1984 Nov;99(5):1613–1623. doi: 10.1083/jcb.99.5.1613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jalkanen S. T., Bargatze R. F., Herron L. R., Butcher E. C. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol. 1986 Oct;16(10):1195–1202. doi: 10.1002/eji.1830161003. [DOI] [PubMed] [Google Scholar]
  19. Jalkanen S., Bargatze R. F., de los Toyos J., Butcher E. C. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol. 1987 Aug;105(2):983–990. doi: 10.1083/jcb.105.2.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kahara N., Ozaki T., Doi T., Nishida K., Kawai A., Shibahara M., Inoue H. CD44 expression in soft tissue sarcomas. Virchows Arch. 2000 Jun;436(6):574–578. doi: 10.1007/s004289900159. [DOI] [PubMed] [Google Scholar]
  21. Kainz C., Kohlberger P., Tempfer C., Sliutz G., Gitsch G., Reinthaller A., Breitenecker G. Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer. 1995 Sep;31A(10):1706–1709. doi: 10.1016/0959-8049(95)00353-k. [DOI] [PubMed] [Google Scholar]
  22. Koopman G., Heider K. H., Horst E., Adolf G. R., van den Berg F., Ponta H., Herrlich P., Pals S. T. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 1993 Apr 1;177(4):897–904. doi: 10.1084/jem.177.4.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mackay C. R., Terpe H. J., Stauder R., Marston W. L., Stark H., Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994 Jan;124(1-2):71–82. doi: 10.1083/jcb.124.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Miyake K., Medina K. L., Hayashi S., Ono S., Hamaoka T., Kincade P. W. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med. 1990 Feb 1;171(2):477–488. doi: 10.1084/jem.171.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Miyake K., Underhill C. B., Lesley J., Kincade P. W. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med. 1990 Jul 1;172(1):69–75. doi: 10.1084/jem.172.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mulder J. W., Wielenga V. J., Polak M. M., van den Berg F. M., Adolf G. R., Herrlich P., Pals S. T., Offerhaus G. J. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut. 1995 Jan;36(1):76–80. doi: 10.1136/gut.36.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Naor D., Sionov R. V., Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319. doi: 10.1016/s0065-230x(08)60101-3. [DOI] [PubMed] [Google Scholar]
  28. Picker L. J., Nakache M., Butcher E. C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol. 1989 Aug;109(2):927–937. doi: 10.1083/jcb.109.2.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ross J. S., del Rosario A. D., Bui H. X., Kallakury B. V., Okby N. T., Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996 Aug;9(8):854–860. [PubMed] [Google Scholar]
  30. Ruiz P., Schwärzler C., Günthert U. CD44 isoforms during differentiation and development. Bioessays. 1995 Jan;17(1):17–24. doi: 10.1002/bies.950170106. [DOI] [PubMed] [Google Scholar]
  31. Röser B., Attewell R., Berg N. O., Rydholm A. Survival in soft tissue sarcoma. Prognostic variables identified by multivariate analysis. Acta Orthop Scand. 1987 Oct;58(5):516–522. doi: 10.3109/17453678709146391. [DOI] [PubMed] [Google Scholar]
  32. Soukka T., Salmi M., Joensuu H., Häkkinen L., Sointu P., Koulu L., Kalimo K., Klemi P., Grénman R., Jalkanen S. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res. 1997 Jun 1;57(11):2281–2289. [PubMed] [Google Scholar]
  33. Sugino T., Gorham H., Yoshida K., Bolodeoku J., Nargund V., Cranston D., Goodison S., Tarin D. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996 Sep;149(3):873–882. [PMC free article] [PubMed] [Google Scholar]
  34. Taubert H., Meye A., Würl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 1996 Sep 15;56(18):4134–4136. [PubMed] [Google Scholar]
  35. Webb D. S., Shimizu Y., Van Seventer G. A., Shaw S., Gerrard T. L. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science. 1990 Sep 14;249(4974):1295–1297. doi: 10.1126/science.1697984. [DOI] [PubMed] [Google Scholar]
  36. Wiklund T., Huuhtanen R., Blomqvist C., Tukiainen E., Virolainen M., Virkkunen P., Asko-Seljavaara S., Björkenheim J. M., Elomaa I. The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur J Cancer. 1996 Feb;32A(2):269–273. doi: 10.1016/0959-8049(95)00520-x. [DOI] [PubMed] [Google Scholar]
  37. Yu C. J., Yang P. C., Shun C. T., Lee Y. C., Kuo S. H., Luh K. T. Overexpression of MUC5 genes is associated with early post-operative metastasis in non-small-cell lung cancer. Int J Cancer. 1996 Dec 20;69(6):457–465. doi: 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES